Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Conditions:   Multiple Myeloma;   Relapsed Refractory Multiple Myeloma Interventions:   Drug: Elotuzumab, pomalidomide, dexamethasone;   Drug: Anti-LAG-3 Monoclonal Antibody BMS-986016, pomalidomide, dexamethasone;   Drug: Anti-TIGIT Monoclonal Antibody BMS-986207, pomalidomide, dexamethasone Sponsors:   Multiple Myeloma Research Consortium;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials